Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
Article Details
- CitationCopy to clipboard
Michaelides MR, Dellaria JF, Gong J, Holms JH, Bouska JJ, Stacey J, Wada CK, Heyman HR, Curtin ML, Guo Y, Goodfellow CL, Elmore IB, Albert DH, Magoc TJ, Marcotte PA, Morgan DW, Davidsen SK
Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
Bioorg Med Chem Lett. 2001 Jun 18;11(12):1553-6.
- PubMed ID
- 11412979 [ View in PubMed]
- Abstract
A novel series of biaryl ether reverse hydroxamate MMP inhibitors has been developed. These compounds are potent MMP-2 inhibitors with limited activity against MMP-1. Select members of this series exhibit excellent pharmacokinetic properties with long elimination half-lives (7 h) and high oral bioavailability (100%).
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) 3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide Stromelysin-1 IC 50 (nM) 57 N/A N/A Details